Income statement
USD
Annual
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Income | -43M | -21M | -5M |
| EBITDA | -35M | -20M | -5M |
| Net Income | -50M | -22M | -5M |
| EPS (Diluted) | — | — | — |
Healthcare
Live Price
Offline$29.06
+0.00% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CinCor Pharma, Inc. (CINC) is a Healthcare stock with a market cap of $1.27B. The stock last traded around $29.06. Baseline metrics include revenue growth of 0.0%, EPS growth of -49.5%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -49.5%, free cash flow -77.3% with operating margin 0.0% and ROIC -34.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CINC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CINC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CINC Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CINC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$4.9M
+77.8% YoY
Free Cash Flow
-$4.4M
+74.5% YoY
Revenue Growth
+0.0%
EPS Growth
-49.5%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Income | -43M | -21M | -5M |
| EBITDA | -35M | -20M | -5M |
| Net Income | -50M | -22M | -5M |
| EPS (Diluted) | — | — | — |
Balance sheet
USD
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Cash & Equivalents | 137M | 26M | 11M |
| Total Assets | 141M | 27M | 12M |
| Total Liabilities | 205M | 54M | 17M |
| Shareholder Equity | -64M | -27M | -5M |
| Total Debt | 0 | 0 | 0 |
| Net Debt | -137M | -26M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
+74.5% YoY
Capital Expenditures
0
Free Cash Flow
4M
+74.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
110.7%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.